Skip to main content

Bender Jeremy's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Nov 18, 2025

Accession no.
0001863107-25-000005
Filed
Nov 18, 2025
Trade date
Nov 15-17, 2025
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $141.6K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bender JeremyCIK 0001863107Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseAcquired+3,570––164,935Direct
Nov 15, 2025Common StockMOption exerciseAcquired+4,750––169,685Direct
Nov 15, 2025Common StockMOption exerciseAcquired+11,687––181,372Direct
Nov 15, 2025Common StockMOption exerciseAcquired+11,687––193,059Direct
Nov 17, 2025Common StockSSaleDisposed−15,894$8.91−$141,615.54177,165Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseDisposed−3,570$0.00$00Direct
Nov 15, 2025Common StockMOption exerciseDisposed−4,750$0.00$019,000Direct
Nov 15, 2025Common StockMOption exerciseDisposed−11,687$0.00$093,504Direct
Nov 15, 2025Common StockMOption exerciseDisposed−11,687$0.00$0140,252Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)